FAAH-IN-6

Cat. No.:	HY-103461
CAS No.:	1143578-94-2
Molecular Formula:	$C_{19}H_{17}F_2N_7O$
Molecular Weight:	397.38
Target:	FAAH
Pathway:	Metabolic Enzyme/Protease; Neuronal Signaling
Storage:	Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 100 mg/mL (251.65 mM; Need ultrasonic)

Preparing Stock Solutions

Solvent / Mass / Concentration	1 mg	5 mg	10 mg
1 mM	2.5165 mL	12.5824 mL	25.1648 mL
5 mM	0.5033 mL	2.5165 mL	5.0330 mL
10 mM	0.2516 mL	1.2582 mL	2.5165 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 90% corn oil
   Solubility: 2.5 mg/mL (6.29 mM); Clear solution; Need ultrasonic

BIOLOGICAL ACTIVITY

Description

FAAH-IN-6 (compound 21d) is a potent, orally active and cross the blood-brain barrier fatty acid amide hydrolase (FAAH) inhibitor with IC_{50}s of 0.72, 0.28 nM for hFAAH, rFAAH, respectively. FAAH-IN-6 shows dose-dependent analgesic efficacy in animal models of both neuropathic and inflammatory pain[1].

IC_{50} & Target

IC_{50}: 0.72 nM (hFAAH); 0.28 nM (rFAAH)[1]

In Vivo

FAAH-IN-6 (compound 21d) (1-10 mg/kg; p.o.) shows significantly ameliorates tactile allodynia in a dose-dependent fashion in SNI-induced neuropathic pain rats model[1].

FAAH-IN-6 (3-10 mg/kg; p.o.) shows significantly ameliorates tactile allodynia of the ipsilateral hind paw in CFA-induced inflammatory pain model[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Kono M, et al. Design, synthesis, and biological evaluation of a series of piperazine ureas as fatty acid amide hydrolase inhibitors. Bioorg Med Chem. 2014 Feb 15;22(4):1468-78.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA